Keyphrases
5-year Survival
10%
Acquired Resistance
7%
Acute Leukemia
11%
Acute Lymphoblastic Leukemia
57%
Acute Myeloid Leukemia
41%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Aprepitant
9%
Average Annual Percentage Change
11%
Azacitidine
6%
BCP-ALL
8%
Blood Progenitor
6%
Bone Marrow
14%
Cancer Registry
8%
Cancer-related Fatigue
9%
CD22
10%
Chemotherapy
10%
Childhood Acute Lymphoblastic Leukemia
9%
Children with Cancer
18%
Chimeric Antigen Receptor T-cell Therapy
7%
Chronic Myeloid Leukemia
10%
Clinical Outcomes
9%
Clinical Practice
6%
Clinical Trials
9%
Clinically Significant
7%
Clofarabine
6%
Complete Remission
6%
Confidence Interval
17%
Dose-limiting Toxicity
7%
DOT1L Inhibitor
9%
Down Syndrome
12%
Drug Development
6%
Dutch
26%
European Medicines Agency
7%
Event-free Survival
8%
Fusion Gene
7%
Gemtuzumab Ozogamicin
17%
Genome Analysis
6%
Hematopoietic Stem Cell Transplantation
11%
Hematopoietic Stem Cells
14%
High Risk
6%
High-risk Neuroblastoma
13%
Hodgkin Lymphoma
7%
Immune Dysregulation
8%
Improved Outcomes
8%
Improved Survival
21%
Incidence Trends
7%
Innovative Therapies
6%
KMT2A
21%
Leukemia
26%
Leukemia Patients
17%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
6%
Medullary Thyroid Cancer
6%
Menin Inhibitors
8%
Minimal Residual Disease
9%
Myelodysplastic Syndrome
6%
Neonate
9%
Netherlands
37%
Neuroblastoma
14%
Newly Diagnosed
19%
Nilotinib
6%
Non-Hodgkin Lymphoma
7%
Normal Blood
7%
Older Adults
16%
Oncology
10%
Overall Survival
14%
Paediatric Strategy Forum
7%
Patient Outcomes
6%
Pediatric
63%
Pediatric Acute Lymphoblastic Leukemia
16%
Pediatric AML
7%
Pediatric Cancer
11%
Pediatric Leukemia
46%
Pediatric Oncology
18%
Pediatric Patients
52%
Pharmacokinetics
30%
Phase II Study
16%
Population Pharmacokinetics
19%
Population-based Study
10%
Preadolescent children
14%
Precision Oncology
13%
Preleukemic
7%
Recommended Phase 2 Dose
7%
Relapsed or Refractory
19%
Relapsed or Refractory Acute Myeloid Leukemia
9%
Risk Factors
6%
RNA Sequencing (RNA-seq)
9%
Sleep Problems
7%
Sleep-wake Rhythm
6%
Solid Tumors
7%
Survival Rate
6%
T Cells
11%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
11%
Targeted Therapy
6%
Targeted Treatment
7%
Treatment Effect
6%
Treatment Response
8%
Wilms Tumor
7%
Working Diagnosis
7%
Young Adolescents
16%
Young Cancer Patients
7%
Medicine and Dentistry
Acute Leukemia
12%
Acute Lymphoblastic Leukemia
54%
Acute Myelogenous Leukemia
15%
Acute Myeloid Leukemia
49%
Adolescence
42%
Adverse Outcome
5%
Anaplastic Lymphoma Kinase
5%
Arm
5%
B Cell
6%
Cancer
12%
Cancer Registry
8%
Cancer-Related Fatigue
6%
Carcinogenesis
7%
Central Nervous System Tumor
5%
Chemotherapy
8%
Childhood Cancer
22%
Clinical Trial
10%
Dexamethasone
9%
Disease
20%
Disease Modifying Therapy
6%
Diseases
14%
Down Syndrome
11%
Event Free Survival
9%
Experimental Therapy
5%
Fusion Gene
7%
Ganglioneuroblastoma
34%
Hazard Ratio
7%
Hematopoietic Cell
13%
Hematopoietic Stem Cell Transplantation
8%
High Throughput Screening
5%
Hodgkin's Lymphoma
8%
Immune Dysregulation
6%
Immunotherapy
18%
Inotuzumab Ozogamicin
13%
Kidney Tumour
7%
Leukemia
21%
Leukemia Cell
5%
Leukemia in Children
11%
Liquid Biopsy
6%
Maintenance Therapy
9%
Malignant Neoplasm
33%
Medicine
7%
Methionine
6%
Minimal Residual Disease
12%
Neoplasm
26%
Oncology
21%
Overall Survival
24%
Pediatric Acute Myeloid Leukemia
42%
Pediatric Cancer
12%
Pediatrics
100%
Pediatrics Patient
30%
Personalized Medicine
14%
Phase II Trials
7%
Progression Free Survival
7%
Randomized Controlled Trial
6%
Retrospective Study
6%
Sleep Waking Cycle
6%
Solid Malignant Neoplasm
7%
Somatics
8%
Survival Rate
7%
T Cell
9%
Targeted Therapy
15%
Temozolomide
6%
Topotecan
6%
Transcriptomics
5%
Treatment Response
8%
Wilms' Tumor
6%